

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

POWER OF ATTORNEY TO PROSECUTE APPLICATIONS BEFORE THE USPTO

I hereby revoke all previous powers of attorney given in the application identified in the attached statement under 37 CFR 3.73(b).

I hereby appoint:

☒ Practitioners associated with the Customer Number: 26263

OR

☐ Practitioner(s) named below (if more than ten patent practitioners are to be named, then a customer number must be used):

Name	Registration Number	Name	Registration Number

as attorney(s) or agent(s) to represent the undersigned before the United States Patent and Trademark Office (USPTO) in connection with any and all patent applications assigned only to the undersigned according to the USPTO assignment records or assignment documents attached to this form in accordance with 37 CFR 3.73(b).

Please change the correspondence address for the application identified in the attached statement under 37 CFR 3.73(b) to:

☒ The address associated with Customer Number: 26263

OR


<input type="checkbox"/> Firm or Individual Name			
Address			
City		State	Zip
Country			
Telephone		Email	

Assignee Name and Address: **MANKIND CORPORATION**
28903 North Avenue Paine
Valencia, CA 91355

A copy of this form, together with a statement under 37 CFR 3.73(b) (Form PTO/SB/96 or equivalent) is required to be filed in each application in which this form is used. The statement under 37 CFR 3.73(b) may be completed by one of the practitioners appointed in this form if the appointed practitioner is authorized to act on behalf of the assignee, and must identify the application in which this Power of Attorney is to be filed.

SIGNATURE of Assignee of Record

The individual whose signature and title is supplied below is authorized to act on behalf of the assignee

Signature		Date 08-14-07
Name	David Thomson	Telephone 661-775-5300
Title	Corp. V.P. # General Counsel	

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: MANNKIND CORPORATION

Docket No.: 40000220-0021-003

Application No./Patent No.: 10/026066

Filed/Issue Date: December 7, 2001

Entitled: EPITOPE SYNCHRONIZATION IN ANTIGEN PRESENTING CELLS

CTL IMMUNO THERAPIES CORP.

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest
(The extent by percentage) of its ownership interest is _____% in the patent application/patent

identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

B. ☒ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: Inventors To: CTL ImmunoTherapies Corporation

The document was recorded in the United States Patent and Trademark Office at Reel 013301, Frame 0682, or for which a copy thereof is attached.

2. From: CTL ImmunoTherapies Corporation To: MannKind Corporation

The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

3. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

4. From: _____ To: _____

The document was recorded in the United States Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

Sheila R. Gibson
Signature

October 1, 2007
Date

Sheila R. Gibson
(415) 882-5072
Attorney of Record, Reg. No. 54,120

COPY- DO NOT RECORD

Delaware

PAGE 1

The First State


I, HARRIET SMITH WINDSOR, SECRETARY OF STATE OF THE STATE OF DELAWARE, DO HEREBY CERTIFY THE ATTACHED IS A TRUE AND CORRECT COPY OF THE CERTIFICATE OF MERGER, WHICH MERGES:

"ALLECURE CORP.", A DELAWARE CORPORATION,

"CTL IMMUNOTHERAPIES CORP.", A DELAWARE CORPORATION,

WITH AND INTO "MANNKIND CORPORATION" UNDER THE NAME OF "MANNKIND CORPORATION", A CORPORATION ORGANIZED AND EXISTING UNDER THE LAWS OF THE STATE OF DELAWARE, AS RECEIVED AND FILED IN THIS OFFICE THE TWENTY-THIRD DAY OF DECEMBER, A.D. 2002, AT 9 O'CLOCK A.M.

A FILED COPY OF THIS CERTIFICATE HAS BEEN FORWARDED TO THE NEW CASTLE COUNTY RECORDER OF DEEDS.



Harriet Smith Windsor
Harriet Smith Windsor, Secretary of State

2254871 8100M

020792240

AUTHENTICATION: 2166069

DATE: 12-23-02

COPY- DO NOT RECORD

STATE OF DELAWARE
SECRETARY OF STATE
DIVISION OF CORPORATIONS
FILED 09:00 AM 12/23/2002
020792240 - 2234871

CERTIFICATE OF OWNERSHIP AND
MERGER OF SUBSIDIARIES INTO PARENT
CERTIFICATE OF OWNERSHIP AND MERGER
MERGING
CTL IMMUNOTHERAPIES CORP. AND ALLECURE CORP.
INTO
MANNKIND CORPORATION

MannKind Corporation, a Delaware corporation (the "Corporation"), does hereby certify:

FIRST: That the Corporation is incorporated pursuant to the General Corporation Law of the State of Delaware.

SECOND: That the Corporation owns all of the outstanding shares of each class of the capital stock of CTL ImmunoTherapies Corp., a Delaware corporation, and all of the outstanding shares of each class of capital stock of AlleCure Corp., a Delaware corporation.

THIRD: That the Corporation, by the following resolutions of its Board of Directors, duly adopted on the 15th day of December, 2002, determined to merge into itself CTL ImmunoTherapies Corp. and AlleCure Corp. on the conditions set forth in such resolutions:

RESOLVED: That MannKind Corporation merge into itself its subsidiary, CTL ImmunoTherapies Corp., and its subsidiary, AlleCure Corp., and assume all of said subsidiaries' liabilities and obligations;

FURTHER RESOLVED: That the President and the Secretary of this Corporation be and they hereby are directed to make, execute and acknowledge a certificate of ownership and merger setting forth a copy of the resolution to merge said CTL ImmunoTherapies Corp. and said AlleCure Corp. into this corporation and to assume said subsidiaries' liabilities and obligations and the date of adoption thereof and to file the same in the office of the Secretary of State of Delaware.

FOURTH: That the mergers of CTL ImmunoTherapies Corp. and AlleCure Corp. into MannKind Corporation shall not become effective upon the filing of this Certificate of Ownership and Merger with the Secretary of State of Delaware, but shall become effective on December 31, 2002.

IN WITNESS WHEREOF, said MannKind Corporation has caused its corporate seal to be affixed and this certificate to be signed by David Thomson, its authorized officer, this 16th day of December, 2002.

MANNKIND CORPORATION

By David Thomson
Title Secretary